<DOC>
	<DOC>NCT01566604</DOC>
	<brief_summary>This study will assess of the efficacy and safety of a once-daily, 50µg inhalation of NVA237 in moderate to severe chronic obstructive pulmonary disease (COPD) patients over 26 weeks treatment.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any studyrelated procedure With moderate to severe stable COPD (Stage II or Stage III). Current or exsmokers who have a smoking history of at least 10 pack years (Ten pack years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years). Postbronchodilator FEV1 ≥30% and &lt; 80% of the predicted normal, and postbronchodilator FEV1/FVC &lt; 0.7 at Visit 2 (Day 14) (post means: record FEV1 and FVC 45 min after administering ipratropium). Symptomatic patients, according to daily electronic diary data between Visit 2 (Day 14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to Visit 3 With a history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count &gt; 600/mm3 (at Visit 2) or onset of symptoms prior to age 40 years. Patients without asthma but who have a blood eosinophil count &gt;600/mm3 at Visit 2 are excluded. Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless confirmed by imaging to be no longer active) or clinically significant bronchiectasis, sarcoidosis and interstitial lung disorder. Patients with lung lobectomy or lung volume reduction or lung transplantation. Patients with known history and diagnosis of α1 antitrypsin deficiency. Patients who have had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the 6 weeks prior to Visit 1 Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
	<keyword>NVA237</keyword>
</DOC>